THE FOLLOWING WILL DETAIL PAST AND FUTURE CLINICAL EVIDENCE
REDUCING EXTRALUMINAL SKIN FLORA ATTACHMENT DURING PIV INSERTION USING THROUGH-THE-NEEDLE INSERTION METHODS
In association with the North American Science Associates (NAMSA), SkyDance demonstrated a 66% reduction in catheter colonization when through-the-needle catheter deployment was compared to the traditional over-the needle configuration in a benchtop scientific study. These results were presented at the Association of Vascular Access 2019 Annual Scientific Meeting, where it was awarded a People’s Choice Award. The full report is available for download.
CLINICAL USABILITY FOCUS GROUP
In October of 2020, a clinical usability focus group will be held to elicit user feedback of the Osprey version 2 PIV in a simulated use environment.
RANDOMIZED CLINICAL TRIALS
ANIMAL - In Q4, 2020, a randomized controlled study will be initiated to evaluate colonization rates between the Osprey PIV and traditional PIVs in an animal model. Study results to be available immediatly upon the completion of the study with publication planned.
HUMAN - Human randomized control study protocol drafts are complete. These will examine insertion success and outcomes related comparative data. They are intended to begin in the second quarter of 2021 with a conclusion in the fourth quarter of that year.